About Us

Committed to Improving Patients' Life

Company Overview

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, HBICE® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. 

 

  1. Our Mission

    Healthy life · Breakthrough Medicines

HBM’s efforts are driven by our vision of delivering “Healthy life · Breakthrough Medicines”. To realize this vision, we have been partnering with global academic institutions, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record of portfolio includes strategically selected co-development clinical assets and internal innovative NextGen projects to address unmet patient’s need. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics.

Corporate Strategy

Our strategic priority is leading next-gen biotherapeutics innovation in global market powered by our proprietary technology platforms and expertise.

 

To advance next-gen biotherapeutic innovation, we established two business units - Harbour Therapeutics and Nona Biosciences as two core pillars. Harbour Therapeutics focuses on advancing the global portfolio of transformative therapeutics, and Nona Biosciences provides wildly open access to HBM technologies and expertise with an innovative business model to accelerate global biotherapeutic innovation and ultimately benefit patients around the world.

  1. Harbour Therapeutics

    Harbour Therapeutics

  2. Nona Biosciences

    Nona Biosciences

Management Team

  • Jingsong Wang
    Jingsong WangMD, PhD
    Founder, Chairman & Chief Executive Officer
  • Yiping Rong
    Yiping RongPhD
    Chief Scientific Officer
  • Xiaolu Tao
    Xiaolu TaoPhD
    President of Harbour Therapeutics
  • Raymond Zheng
    Raymond ZhengPhD
    Chief Business Officer
  • Michael D. Patten
    Michael D. Patten
    Chief Strategy Officer
  • Ben Chih
    Ben ChihPhD
    Chief Scientific Officer - Neurosciences, Entrepreneur in Residence, Harbour BioMed US
  • Youchen Chen
    Youchen Chen
    Vice President, Head of Finance and Investor Relations
  • Ian Y. Liu
    Ian Y. LiuJD, PhD
    Senior Vice President, Global Head of Legal
Jingsong Wang
Jingsong WangMD, PhD

Founder, Chairman & Chief Executive Officer

Dr. Jingsong Wang, is our Principal Founder, Chairman and Chief Executive Officer. Prior to founding our company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.

Yiping Rong
Yiping RongPhD

Chief Scientific Officer

Dr. Yiping Rong is CSO of Harbour BioMed. He is a well-recognized scientist with about 20 years' experience of biomedical research and drug discovery. Prior to joining Harbour BioMed in 2016, he worked in Sanofi, JNJ and Roche and built strong expertise in cancer biology and pharmacology. He led and contributed to >15 programs entering clinical trials. He is also involved in translational research work for a few drugs. Multiple mAb or bispecific antibodies generated from his team were out licensed to MNCs. Some highly innovative first-in-class projects are in clinical trials. He worked on apoptosis, epigenetics, immuno-oncology, and cancer cell signaling fields and led the drug discovery projects including kinase, enzyme, receptor/ligand, protein-protein-interaction targets by small molecules or monoclonal antibodies. Dr. Rong received his Ph.D. degree in Pharmacology from Case Western Reserve University (Cleveland, Ohio). He is the member of American Association of Cancer Research and has more than twenty publications in cancer research field, including Nature Genetics, Molecular Cell, PNAS papers. He is also the inventor of dozens of patents in drug discovery field.

Xiaolu Tao
Xiaolu TaoPhD

President of Harbour Therapeutics

Dr. Xiaolu Tao is currently President of Harbour Therapeutics. She has more than ten years of experience in drug R&D in the United States, and has been responsible for the translational medicine and clinical pharmacology of developing chemical drugs, biological drugs and biosimilars in internationally renowned pharmaceutical companies such as Bristol Myers Squibb (BMS) and Novartis. The projects that she was responsible for or supported include: Belatacept (Nulojix®), which has been approved in the United States, Europe, and many other regions of the world; new formulation of biosimilar Binocrit® approved in Europe; as well as the global development of clinical stage anti-IP10 humanized antibody Eldelumab; Daclatasvir-TRIO for hepatitis C; and biosimilars of bevacizumab and aflibercept.

 

Dr. Tao returned to China in 2016, and then worked as Head of Clinical Pharmacology in Simcere Pharmaceutical and CStone Pharmaceuticals, building and managing the clinical pharmacology team. During this period, she was responsible for the bridging study and successful approval in China of Abatecept (Orencia®) and supported several global clinical trials of multiple molecules. Under her supporting, sugemalimab (anti-PD-L) successfully received the ODD and BTD designations from the FDA; Pralsetinib and Avapritinib successfully submitted the NDAs in China; and Ivosidenib successfully submitted the NDA in Taiwan, China. After joining Harbour BioMed, Dr. Tao served as Vice President of Translational Development and Early Clinical Development as well as Chief Product Development Officer, with overall responsibility for the company's clinical pipelines. In the past few years, several FIC products have received IND approvals and entered clinical development in the United States and China.

Raymond Zheng
Raymond ZhengPhD

Chief Business Officer

Dr. Raymond Zheng is CBO of Harbour BioMed. Based in the United States, Dr. Zheng leads global business development and alliance management functions. He was initially trained as a scientist and completed a research fellowship in the field of translational oncology at Harvard Medical School before joining the biopharmaceutical industry. Prior to Harbour BioMed, Dr. Zheng served as founder and CSO of Urica Therapeutics, a clinical-stage company developing an oral therapy for refractory gout. During his tenure at Urica, early clinical development was completed, and the asset was subsequently acquired by a Newco backed by venture capital committed to supporting its pivotal development. He also made significant contributions at Fortress Biotech and Agenus as a business developer where he managed value-added investments and negotiated transformative partnership transactions.

 

Dr. Zheng holds a Ph.D. in Cell and Molecular Biology from the University of California, Riverside, and an MBA in Finance from Rutgers University.

Michael D. Patten
Michael D. Patten

Chief Strategy Officer

Michael D. Patten is Chief Strategy Officer of Harbour BioMed. Based in the United States, Michael is responsible for formulating and overseeing the global business development strategy and growth strategy for Harbour BioMed. He leads efforts to manage and strengthen Harbour BioMed’s global strategic partner network and ecosystem, with a particular focus on high-potential markets outside of China, further enhancing Harbour BioMed’s global presence.

 

Michael brings extensive experience and a strong track record in the biopharmaceutical industry. During his tenure at Bristol Myers Squibb, he held several key leadership roles. Most recently, as Head of Equity & Venture Capital, he led and managed several strategic equity investments and LP commitments across the life science ecosystem. Prior, he held roles of increasing seniority in Business Development and Alliance Leadership, successfully executing transactions and managing multiple early- and late-stage business development alliances, demonstrating exceptional expertise in business development and alliance management.

 

Michael holds a Bachelor of Science with Joint Honors in Pharmacology & Business Studies from the University of Edinburgh, a Master of Science in Pharmaceutical Medicine from the University of Surrey, and an MBA from the University of Maastricht (EuroMBA Consortium).

Ben Chih
Ben ChihPhD

Chief Scientific Officer - Neurosciences, Entrepreneur in Residence, Harbour BioMed US

Dr. Ben Chih is Chief Scientific Officer of Neurosciences, Harbour BioMed US. He is a seasoned neuroscientist with 18 years of industry experience in drug discovery for neuroscience, including 13 years at the renowned Genentech. Ben holds a bachelor's degree in molecular biology from Carnegie Mellon University and a PhD in Physiology from Columbia University. Before joining Harbour BioMed US, Dr. Chih served as Entrepreneur-In-Residence at 82VS Venture Studio and Alloy Therapeutics Inc. He co-founded Restoration Biosciences and Aldebaran Therapeutics, where he spearheaded the development of innovative therapies targeting neuroinflammation and ocular diseases. Prior to his entrepreneurial ventures, Dr. Chih held the position of project team leader at prominent biotech companies like Elan and Genentech.

 

Dr. Chih's expertise spans neurodegeneration, brain shuttle antibody technologies, oligonucleotide drug discovery, and human iPSC disease modeling. His contributions to the field have been recognized with the prestigious Genentech Innovation Award. He is a co-inventor on 7 patents and has authored 16 publications in top-tier journals, including Science, Neuron, Nature Cell Biology, and Nature Communications.

 

In his role as Chief Scientific Officer of Neurosciences, Dr. Chih will be responsible for incubating the NewCo and translating the concept into practice. He will develop and execute the company's scientific vision and strategy, aligning it with the company's business goals. Additionally, Dr. Chih will build and nurture scientific innovation and the US business ecosystem to support the company's growth needs. With his wealth of experience, expertise, and proven track record, Dr. Ben Chih is poised to lead the company's neuroscience initiatives, driving innovation, and advancing the frontiers of drug discovery in this critical field.

Youchen Chen
Youchen Chen

Vice President, Head of Finance and Investor Relations

Mr. Youchen (YC) Chen is Vice President and Head of Finance and Investor Relations. At Harbour BioMed, YC is responsible for developing and managing global financial strategy, corporate strategy, investments, capital markets and investor relations functions.

 

YC holds a Bachelor in law from Fudan University and an MBA from McDonough School of Business, Georgetown University. Before joining Harbour BioMed, he was CFO at a clinical-stage radiopharmaceutical startup and also worked as Senior Vice President in the China Investment Banking team at Credit Suisse, advising Greater China healthcare and tech companies on strategic and financing transactions. Prior to rejoining Credit Suisse, he worked as Head of Corporate Finance at Yidu Tech (2158. HK) and held multiple roles at CITIC Capital and KPMG.

Ian Y. Liu
Ian Y. LiuJD, PhD

Senior Vice President, Global Head of Legal

Dr. Ian Y. Liu is Senior Vice President, Global Head of Legal of Harbour BioMed. Based in the United States, Dr. Liu oversees business development transactions, ensuring legal and regulatory compliance while facilitating seamless execution to safeguard the company’s interests. He also leads the company’s global intellectual property strategy. Additionally, Dr. Liu takes full responsibility for U.S. -related legal affairs, managing significant legal matters, including lawsuits, protecting the company's business operations in the region, and supporting its strategic growth in the U.S. market.

 

Before joining Harbour BioMed, Dr. Liu worked at renowned law firms, including Finnigan, Henderson, Farabow, Garrett & Dunner, LLP, and K&L Gates, LLP, where he gained extensive experience in patent applications, litigation, and due diligence. In the corporate legal affairs sector, he held key positions such as Head of Legal and Governmental Affairs at Simcere Pharmaceutical, demonstrating exceptional ability in handling complex legal matters and commercial negotiations.

 

Dr. Liu holds a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a J.D. from Suffolk University Law School.

Scientific Advisory Board

  • Frank Grosveld
    Frank GrosveldPhD
    Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam
  • Robert Kamen
    Robert KamenPhD
    Entrepreneur in Residence
    Advisory Partner, Third Rock Ventures
    Independent Non-Executive Director, Harbour BioMed
  • Jon Wigginton
    Jon WiggintonMD
    CMO, Cullinan Oncology
    Advisor, PMP Capital
  • Robert Kramer
    Robert KramerPhD
    CSO, SalvaRx Therapeutics
    BoD, Meditope Biosciences
    Chair, NeoTX SAB
  • Peter Moesta
    Peter MoestaPhD
    Chief CMC Advisor, Harbour BioMed
    Former CEO, Adello Biologics
  • Zhigang Tian
    Zhigang TianPhD
    Academician of Chinese Academy of Engineering
    Member of Academia Europaea
    Professor, School of Life Sciences; Dean, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science & Technology of China (USTC)
    Director, Institute of Immunology, USTC
    Director, The Key Lab of Innate Immunity and Chronic Disease, Chinese Academy of Science
Frank GrosveldPhD
Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam

Frank Grosveld, Ph.D., has served on our scientific advisory board since December 2016. Dr. Grosveld is Co-Founder and CSO of Harbour Antibodies and the inventor of Harbour Mice®, Professor and former Head of Department of Cell Biology and Department of Clinical Genetics at Erasmus University Medical Center, Rotterdam, a fellow of Royal Society and a member of Royal Netherlands Academy of Arts and Sciences. Dr. Grosveld's research on the control of globin gene expression has been selected as one of the top ten achievements of Medical Research Council (UK) (MRC) in the 20th century by Higher Education and Research Opportunities in the U.K. Dr. Grosveld was awarded the Louis-Jeantet Prize for Medicine in 1991, the Spinozapremie (Spinoza Prize) in 1995.

Robert KamenPhD
Entrepreneur in Residence
Advisory Partner, Third Rock Ventures
Independent Non-Executive Director, Harbour BioMed

Robert Kamen, Ph.D., has served on our scientific advisory board since 2016. Dr. Kamen is an Advisory Partner at Third Rock Ventures. In 2005, he co-founded BioAssets Development Corporation and served as its Chairman. He currently serves as an Independent Non-Executive Director of the Company and a Director of Jounce Therapeutics. He was previously a Director of Neon Therapeutics and Harbour Antibodies. Earlier in his career, he was Senior Vice President of Scientific Affairs at the pioneering biotechnology firm named Genetics Institute, Inc. Dr. Kamen received his bachelor's degree in biophysics from Amherst College, a Ph.D. in biochemistry and molecular biology from Harvard University Graduate School of Arts and Sciences. During his academic scientific career, he worked at the Imperial Cancer Research Fund.

Jon WiggintonMD
CMO, Cullinan Oncology
Advisor, PMP Capital

Jon Wigginton, M.D., has served on our scientific advisory board since May 2020. Dr. Wigginton currently serves as Chief Medical Officer, Cullinan Oncology, and Advisor, MPM Capital. He previously served as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a Maryland biotechnology company focused on immunotherapeutic approaches for cancer and autoimmune disease. Prior to MacroGenics, Dr. Wigginton served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1 among others. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic, translational and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer.

Robert KramerPhD
CSO, SalvaRx Therapeutics
BoD, Meditope Biosciences
Chair, NeoTX SAB

Robert Kramer, Ph.D., has served on our scientific advisory board since December 2016. Dr. Kramer serves as CSO of Portage Biotech Inc. Dr. Kramer previously served as Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnson and Johnson), where he was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Prior to joining Janssen Research & Development, LLC, Dr. Kramer served as VP Drug Discovery and Research for Bristol-Myers Squibb (BMS), where he provided scientific leadership and strategic oversight for many pre-clinical Oncology and Immunology programs and projects that entered development. Dr. Kramer was previously an Assistant Professor at Harvard Medical School. Dr. Kramer received his Ph.D. in pharmacology from the University of Vermont and completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health.

Peter MoestaPhD
Chief CMC Advisor, Harbour BioMed
Former CEO, Adello Biologics

Peter Moesta, Ph.D., has served on our scientific advisory board since December 2016. He oversaw the development, production and worldwide launch of important medicines, such as Humira, Yervoy and Opdivo. Dr. Moesta previously served in executive roles at Bristol-Myers Squibb.

Zhigang TianPhD
Academician of Chinese Academy of Engineering
Member of Academia Europaea
Professor, School of Life Sciences; Dean, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science & Technology of China (USTC)
Director, Institute of Immunology, USTC
Director, The Key Lab of Innate Immunity and Chronic Disease, Chinese Academy of Science

Zhigang Tian, Ph.D., has served on our scientific advisory board since August 2020. Dr. Tian is an academician of Chinese Academy of Engineering, a member of Academia Europaea and a medical immunologist. Currently, he is a professor at University of Science and Technology of China (USTC), where he also works as Dean at School of Basic Medical Sciences, and Director at Institute of Immunology. He is also the Director of the Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science.

 

Dr. Tian was awarded with the National Science Fund for Distinguished Young Scholars. He is the Academic Leader of Chang Jiang Scholars Program as well as the Innovation Research Program of National Natural Science Foundation of China. Dr. Tian is Head of National Science and Technology Major Project and Chief Scientist of National Major Research Plan Program.

 

Dr. Tian's laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK)cells,particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy.

Our History